Certriad Approval Status
- FDA approved: No
- Brand name: Certriad
- Generic name: rosuvastatin calcium and fenofibric acid
- Company: Abbott and AstraZeneca
- Treatment for: High Cholesterol, Hypertriglyceridemia, Hyperlipoproteinemia
Certriad (rosuvastatin calcium and fenofibric acid) is a combination of the active ingredients in Crestor and Trilipix intended for the treatment of mixed dyslipidemia.
In March 2010, AstraZeneca and Abbott announced the receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA), advising the company that the New Drug Application (NDA) for Certriad (rosuvastatin/fenofibric acid delayed release) capsules had not been approved.
Development Status and FDA Approval Process for Certriad
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.